More may not be better: reconsidering early clinical trial design in the era of targeted cancer therapeutics
The advent of a new generation of targeted cancer drugs requires a radically different design of early clinical trials. Here, René Bernards discusses why new clinical trial designs are needed and what is being done to achieve this. Such innovative trials can lead to similar outcomes for cancer patie...
Main Author: | René Bernards |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2023-03-01
|
Series: | Molecular Oncology |
Subjects: | |
Online Access: | https://doi.org/10.1002/1878-0261.13391 |
Similar Items
-
Drug Development in Soft Tissue Sarcomas: Novel Targets and Recent Early Phase Trial Results
by: Ella Achenbach, et al.
Published: (2020-05-01) -
Clinical Predictors of Early Trial Discontinuation for Patients Participating in Phase I Clinical Trials in Oncology
by: Joeri A. J. Douma, et al.
Published: (2021-05-01) -
Controversial statistical issues in clinical trials /
by: Chow, Shein-Chung, 1955- 323859
Published: (c201) -
Should We Design Clinical Trials Differently in the Era of Cancer Immunotherapy?
by: Chia-Chi Lin
Published: (2019-05-01) -
An introduction to statistics in early phase trials /
by: 271784 Julious, Steven A., et al.
Published: (2010)